Peripartum Cardiomyopathy in Nigeria Registry

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 100 participants.

Also called NCT03081949

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 100 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT03081949
Main results
  • Selenium supplementation in patients with peripartum cardiomyopathy: a proof-of-concept trial BMC cardiovascular disorders, 2020-10-21 DOI, PubMed 33087055, PMC7579991 PubMed links an erratum for this paper. Erratum: PMID 33397290 In the PMC Open Access subset under CC BY.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Nigeria (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03081949. Randomized; no masking; primary purpose treatment. Start 2017-06-12 (actual); primary completion 2019-06-30 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Peripartum Cardiomyopathy in Nigeria Registry
Acronym
PEACE
Condition
Peripartum Cardiomyopathy
Intervention (Drug)
Oral Sodium Selenite 200 µg/day for 3 months
Lead sponsor
Aminu Kano Teaching Hospital (class: other)
Collaborator
Nigerian Cardiac Society (class: not stated)

Record details

Record id
cardio:ct-nct03081949
Content hash
d3dafd13d8b1ba6b27d6a26e24b0959e48cf49c00d2656ef2b93d3b04b5d9d1e